Promoting Open Access to Exploring the Research

Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance

Wright, A and Zignol, M and Van Deun, A and Falzon, D and Gerdes, SR and Feldman, K and Hoffiner, S and Drobniewski, F and Berrera, L and Van Soolingen, D and Boulabhal, F and Paramasivan, CN and Kam, K M and Mitarai, S and Nunn, P and Raviglione, M (2009) Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 373 (9678). pp. 1861-1873. ISSN 0140-6736

[img] Archive
200926.pdf - Published Version
Restricted to Registered users only

Download (533kB) | Request a copy
Official URL: http://www.thelancet.com/journals/lancet/article/P...

Abstract

BACKGROUND: The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide. Methods Data for drug susceptibility were gathered from 90 726 patients in 83 countries and territories between 2002 and 2007. Standardised collection of results enabled comparison both between and within countries. Where possible, data for HIV status and resistance to second-line drugs were also obtained. Laboratory data were quality assured by the Supranational Tuberculosis Reference Laboratory Network. FINDINGS: The median prevalence of resistance to any drug in new cases of tuberculosis was 11·1% (IQR 7·0–22·3). The prevalence of multidrug resistance in new tuberculosis cases ranged from 0% in eight countries to 7% in two provinces in China, 11·1% in Northern Mariana Islands (although reporting only two cases), and between 6·8% and 22·3% in nine countries of the former Soviet Union, including 19·4% in Moldova and 22·3% in Baku, Azerbaijan (median for countries surveyed 1·6%, IQR 0·6–3·9). Trend analysis showed that between 1994 and 2007, the prevalence of multidrug-resistant (MDR) tuberculosis in new cases increased substantially in South Korea and in Tomsk Oblast and Orel Oblast, Russia, but was stable in Estonia and Latvia. The prevalence of MDR tuberculosis in all tuberculosis cases decreased in Hong Kong and the USA. 37 countries and territories reported representative data on extensively drugresistant (XDR) tuberculosis. Five countries, all from the former Soviet Union, reported 25 cases or more of XDR tuberculosis each, with prevalence among MDR-tuberculosis cases ranging between 6·6% and 23·7%. INTERPRETATION: MDR tuberculosis remains a threat to tuberculosis control in provinces in China and countries of the former Soviet Union. Data on drug resistance are unavailable in many countries, especially in Africa, emphasising the need to develop easier methods for surveillance of resistance in tuberculosis. FUNDING: Global Project: United States Agency for International Development and Eli Lilly and Company. Drug resistance surveys: national tuberculosis programmes, the Government of the Netherlands, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Japan International Cooperation Agency, and Kreditanstalt für Wiederaufbau.

NIRT Creators:
NIRT CreatorsEmail
Item Type: Article
Uncontrolled Keywords: Epidemiology; antituberculosis; drug resistance; Surveillance
Subjects: Tuberculosis > Laboratory Research > Bacteriological
Divisions: Basic Science Research > Bacteriology
Depositing User: Dr. Rathinasabapati R
Date Deposited: 13 Nov 2017 10:45
Last Modified: 13 Nov 2017 10:55
URI: http://eprints.nirt.res.in/id/eprint/950

Actions (login required)

View Item View Item